Mark Lappe Biography and Net Worth

Mr. Lappe co-founded Inhibrx in 2010 and has served as Chief Executive Officer since our inception. He also serves as the Chairman of our Board of Directors. Mr. Lappe has extensive expertise in the biotechnology industry with over thirty years of experience in executive management, investment management, and executive recruiting, having built the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mr. Lappe was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies.

What is Mark Lappe's net worth?: The estimated net worth of Mark Lappe is at least $60.53 million as of September 12th, 2024. Mr. Lappe owns 692,511 shares of Inhibrx Biosciences stock worth more than $60,532,387 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Lappe may own. Additionally, Mr. Lappe receives an annual salary of $1,100,000.00 as CEO at Inhibrx Biosciences. Learn More about Mark Lappe's net worth.
How old is Mark Lappe?: Mr. Lappe is currently 57 years old. There are 3 older executives and no younger executives at Inhibrx Biosciences. Learn More on Mark Lappe's age.
What is Mark Lappe's salary?: As the CEO of Inhibrx Biosciences, Inc., Mr. Lappe earns $1,100,000.00 per year. Learn More on Mark Lappe's salary.
How do I contact Mark Lappe?: The corporate mailing address for Mr. Lappe and other Inhibrx Biosciences executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx Biosciences can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Mark Lappe's contact information.
Has Mark Lappe been buying or selling shares of Inhibrx Biosciences?: Mark Lappe has not been actively trading shares of Inhibrx Biosciences in the last ninety days. Most recently, on Monday, September 16th, Mark Lappe bought 13,037 shares of Inhibrx Biosciences stock. The stock was acquired at an average cost of $17.13 per share, with a total value of $223,323.81. Following the completion of the transaction, the chief executive officer now directly owns 705,548 shares of the company's stock, valued at $12,086,037.24. Learn More on Mark Lappe's trading history.
Who are Inhibrx Biosciences' active insiders?: Inhibrx Biosciences' insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), Jon Kayyem (Director), Mark Lappe (Founder), Mark Lappe (CEO), and Kristiina Vuori (Director). Learn More on Inhibrx Biosciences' active insiders.
Are insiders buying or selling shares of Inhibrx Biosciences?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 350,000 shares worth more than $11,287,500.00. The most recent insider tranaction occured on October, 7th when Major Shareholder Global Investors Lp Viking sold 350,000 shares worth more than $11,287,500.00. Insiders at Inhibrx Biosciences own 17.1% of the company. Learn More about insider trades at Inhibrx Biosciences.
Information on this page was last updated on 10/7/2025.

Mark Lappe Insider Trading History at Inhibrx Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/16/2024	Buy	13,037	$17.13	$223,323.81	705,548
9/12/2024	Buy	26,963	$15.05	$405,793.15	692,511
9/9/2024	Buy	9,500	$15.21	$144,495.00	657,048
9/6/2024	Buy	26,000	$15.29	$397,540.00	647,548
9/3/2024	Buy	20,000	$15.81	$316,200.00	165,000
8/29/2024	Buy	10,000	$14.03	$140,300.00	135,000
1/23/2023	Sell	21,665	$25.36	$549,424.40	2,490,587
12/19/2022	Sell	26,000	$25.56	$664,560.00	2,512,252
10/17/2022	Sell	26,000	$29.59	$769,340.00	2,564,252

Mark Lappe Buying and Selling Activity at Inhibrx Biosciences

Inhibrx Biosciences Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Today's Range

Now: $87.41

$81.49

$89.43

50 Day Range

MA: $61.01

$28.36

$87.41

2 Week Range

Now: $87.41

$10.81

$89.43

Volume

275,711 shs

Average Volume

261,355 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Mark Lappe Biography and Net Worth

What is Mark Lappe's net worth?

How old is Mark Lappe?

What is Mark Lappe's salary?

How do I contact Mark Lappe?

Has Mark Lappe been buying or selling shares of Inhibrx Biosciences?

Who are Inhibrx Biosciences' active insiders?

Are insiders buying or selling shares of Inhibrx Biosciences?